Helicobacter pylori: Strategies to Mitigate Antimicrobial Resistance

Abstract

Introduction: Helicobacter pylori, a gram-negative, spiral-shaped bacterium, is involved in the pathogenesis of several gastrointestinal disorders, ranging from mild gastric ulcers to severe conditions such as chronic gastritis, MALT lymphoma, and gastric cancer. This review examines the various factors that contribute to the persistence of H. pylori and its increasing antibiotic resistance. Methods: Articles from multiple databases, including PubMed, Sci-Hub, Google Scholar, Gavin Publishers, and MDPI (Multidisciplinary Digital Publishing Institute), were sourced. The keywords used during the search process were “H. pylori”, “Electrobacter pylori”, “Antibiotic resistance in gastric ulcer patients”, “Antibiotic resistance to H. pylori”, and “H. pylori in connection to gastric ulcers.” Data extraction followed a systematic approach. Information from the selected articles was gathered by reviewing the title, abstract, and full text to ensure alignment with the review topic. Results: The study revealed that Helicobacter pylori causes cellular dysregulation and chronic inflammation, which are attributed to its virulence factors: CagA and VacA. These proteins, VacA and CagA, harm the host DNA repair systems, which raises the chances of malignant development by causing oxidative stress and epigenetic modifications. Discussion: A major obstacle to the successful eradication therapy of H. pylori is its antibiotic resistance, which is linked to its capacity to create biofilms and activate efflux pumps. This renders typical treatment plans like triple therapy, which involves omeprazole, amoxicillin, and clarithromycin, ineffective. The failure of current antibiotic therapy has increased the need for research into alternative treatments, techniques, and drugs, including potassium-competitive acid blockers and probiotic supplements, which have proven effective in improving eradication rates and lowering the recurrence of H. pylori infections. In addition, advanced diagnostic methods such as non-invasive molecular assays and next-generation sequencing now enable more precise determination of resistant profiles and help in the customization of therapeutic approaches against H. pylori. Conclusion: Insight into molecular and clinical data of H. pylori infections has highlighted the necessity for creative, locally specific therapies that address the immediate pathogenic consequences as well as the more general issues of antibiotic resistance in H. pylori. This emphasizes the significance of studies like ours that examine the resistance of H. pylori infections to antibiotics. Future research should focus on refining diagnostic tools, exploring novel therapeutic agents, and improving public health initiatives to curb the emergence of resistant H. pylori strains.